Foster & Motley Inc. Grows Holdings in Abbott Laboratories $ABT

Foster & Motley Inc. increased its holdings in Abbott Laboratories (NYSE:ABT) by 10.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,506 shares of the healthcare product maker’s stock after acquiring an additional 435 shares during the quarter. Foster & Motley Inc.’s holdings in Abbott Laboratories were worth $613,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Hughes Financial Services LLC bought a new stake in Abbott Laboratories during the first quarter valued at $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter worth about $28,000. Elequin Capital LP bought a new stake in Abbott Laboratories during the first quarter worth approximately $30,000. JCIC Asset Management Inc. bought a new position in Abbott Laboratories during the first quarter valued at about $32,000. Finally, Vision Financial Markets LLC bought a new position in shares of Abbott Laboratories during the 1st quarter valued at about $33,000. Institutional investors own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.46% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ABT has been the subject of a number of recent analyst reports. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. Wells Fargo & Company increased their price objective on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a report on Thursday. Mizuho lifted their target price on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Raymond James Financial upped their price target on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Barclays raised their target price on shares of Abbott Laboratories from $159.00 to $162.00 and gave the company an “overweight” rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $147.61.

Abbott Laboratories Trading Up 0.8%

Shares of ABT stock opened at $128.69 on Monday. The stock has a market cap of $223.98 billion, a price-to-earnings ratio of 16.13, a P/E/G ratio of 2.44 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The firm has a fifty day moving average of $132.38 and a 200-day moving average of $131.54.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.30. The company had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.